Cohen Milstein Sellers & Toll PLLC is investigating a potential action against Novartis relating to the company’s intentional failure to warn of dangerous vascular risks associated with its drug Tasigna.

Tasigna is a prescription medication intended for treatment of chronic myeloid leukemia. Prior to the expiration of their patent on Gleevec in 2015, Novartis developed Tasigna as a replacement and began an aggressive marketing campaign to encourage doctors to prescribe Tasigna over Gleevec.

Throughout the campaign, Novartis failed to warn doctors and patients of the risk that Tasigna has been shown to cause severe, accelerated, and irreversible forms of atherosclerosis-related conditions – i.e., the narrowing and hardening of arteries delivering blood to the arms, legs, heart, and brain.

Novartis has been aware of this risk since 2011. However, despite issuing an appropriate warning to doctors and patients in Canada, Novartis intentionally failed to provide a similar warning to doctors and patients in the United States.

If you or a loved one have taken Tasigna and have experienced any of the side effects referenced above, please take a moment to fill out the questionnaire below. We will contact you within two business days to schedule a time to discuss our investigation.


Personal Information:

Contact Information:

Geoffrey Graber, Partner  - ggraber@cohenmilstein.com
Cohen Milstein Sellers & Toll PLLC
1100 New York Avenue, N.W.
Fifth Floor
Washington, D.C. 20005
Tel: (888) 240-0775 or (202) 408-4600
Fax: (202) 408-4699